Compass Therapeutics Book Value Per Share Growth & History (CMPX)
Compass Therapeutics's book value per share was $1.10 for fiscal 2025.
View full Compass Therapeutics company overviewCompass Therapeutics annual book value per share history
| Fiscal year | Period ended | Book value per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.10 | $0.19 | +21.45% |
| 2024 | 2024-12-31 | $0.91 | -$0.25 | −21.90% |
| 2023 | 2023-12-31 | $1.16 | -$0.27 | −19.10% |
| 2022 | 2022-12-31 | $1.44 | $0.05 | +3.52% |
| 2021 | 2021-12-31 | $1.39 | $0.61 | +78.14% |
| 2020 · Dec 31 | 2020-12-31 | $0.78 | -$0.82 | −51.31% |
| 2020 · Mar 31 | 2020-03-31 | -$24.95 | -$24.94 | — |
| 2019 · Dec 31 | 2019-12-31 | $1.60 | — | — |
| 2019 · Mar 31 | 2019-03-31 | -$0.01 | — | — |
Compass Therapeutics quarterly book value per share
| Fiscal quarter | Period ended | Book value per share | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $0.92 | $0.25 | +36.79% |
| Q1 2026 | 2026-03-31 | $1.04 | $0.24 | +29.84% |
| Q4 2025 | 2025-12-31 | $1.10 | $0.19 | +21.45% |
| Q3 2025 | 2025-09-30 | $1.18 | $0.17 | +17.35% |
| Q2 2025 | 2025-06-30 | $0.67 | -$0.39 | −36.52% |
| Q1 2025 | 2025-03-31 | $0.80 | -$0.34 | −30.14% |
| Q4 2024 | 2024-12-31 | $0.91 | -$0.25 | −21.90% |
| Q3 2024 | 2024-09-30 | $1.01 | -$0.25 | −19.90% |
| Q2 2024 | 2024-06-30 | $1.06 | -$0.26 | −19.62% |
| Q1 2024 | 2024-03-31 | $1.14 | -$0.25 | −17.69% |
| Q4 2023 | 2023-12-31 | $1.16 | -$0.27 | −19.10% |
| Q3 2023 | 2023-09-30 | $1.26 | $0.11 | +9.27% |
| Q2 2023 | 2023-06-30 | $1.32 | $0.06 | +5.09% |
| Q1 2023 | 2023-03-31 | $1.39 | $0.05 | +4.05% |
| Q4 2022 | 2022-12-31 | $1.44 | $0.05 | +3.52% |
| Q3 2022 | 2022-09-30 | $1.15 | $0.76 | +197.14% |
| Q2 2022 | 2022-06-30 | $1.26 | $0.79 | +168.47% |
| Q1 2022 | 2022-03-31 | $1.33 | $0.68 | +104.33% |
| Q4 2021 | 2021-12-31 | $1.39 | $0.61 | +78.14% |
| Q3 2021 | 2021-09-30 | $0.39 | -$0.54 | −58.26% |
| Q2 2021 · Jun 30 | 2021-06-30 | $0.47 | -$0.58 | −55.24% |
| Q1 2021 · Mar 31 | 2021-03-31 | $0.65 | $25.60 | — |
| Q4 2020 · Dec 31 | 2020-12-31 | $0.78 | -$0.82 | −51.31% |
| Q2 2021 · Sep 30 | 2020-09-30 | $0.93 | $23.37 | — |
| Q1 2021 · Jun 30 | 2020-06-30 | $1.05 | $21.83 | — |
| Q4 2020 · Mar 31 | 2020-03-31 | -$24.95 | -$24.94 | — |
| Q4 2019 · Dec 31 | 2019-12-31 | $1.60 | $1.61 | — |
| Q2 2020 | 2019-09-30 | -$22.44 | -$22.43 | — |
| Q1 2020 | 2019-06-30 | -$20.78 | -$20.77 | — |
| Q4 2019 · Mar 31 | 2019-03-31 | -$0.01 | -$0.01 | — |
| Q3 2019 | 2018-12-31 | -$0.01 | — | — |
| Q2 2019 | 2018-09-30 | -$0.01 | — | — |
| Q1 2019 | 2018-06-30 | -$0.01 | — | — |
| As of Mar 31, 2018 | 2018-03-31 | -$0.01 | — | — |
Compass Therapeutics book value per share trends
Over the last five fiscal years, Compass Therapeutics's book value per share increased from $0.78 to $1.10, a change of $0.32. The latest reported quarter, Q2 2026, shows $0.92.
What book value per share means
Book value per share estimates the common shareholders’ accounting equity represented by each share. It can help compare a company’s balance-sheet value over time, although market value can differ substantially from book value.
How book value per share is calculated
TickerStat calculates book value per share as SEC-reported common shareholders’ equity divided by reported period-end common shares. Preferred equity is subtracted when separately reported, and basic weighted-average shares are used only when period-end shares are unavailable. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Compass Therapeutics source filings ↗